Interleukin Genetics and Metagenics have entered into an agreement to incorporate Interleukin's PerioPredict test into Metagenics' employee benefit plan.
PerioPredict will be used to help identify individuals who may benefit from enhanced dental care to prevent and treat periodontitis to help reduce their systemic inflammatory burden to enhance prevention and management of chronic diseases, according to the companies.
Under the terms of the agreement, Interleukin will provide genetic testing and patient education to Metagenics' employees and also offer "dental professional support" to their dental providers.
"We are excited to introduce PerioPredict as a covered benefit in our employee health plans," stated Allison Musetich, chief human resources officer for Metagenics, in a press release. "Genetic testing is beginning to provide us with a real opportunity for enhanced health through knowledge of individual risk factors."
